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study was to perform a cost-effectiveness analysis of ﬁrst-line
monotherapy medications for the treatment of glaucoma.
METHODS: This study was a cost-effectiveness analysis of
latanoprost, brimonidine and beta-blockers for treatment of
glaucoma. Data for the study came from a VA medical center.
Patients were eligible if they had a prescription for latanoprost,
brimonidine or beta-blockers as monotherapy for glaucoma. The
outcomes of interest were change and percent change in intraoc-
ular pressure (IOP). The perspective of the analysis was from that
of a VA medical center and included direct medical costs.
RESULTS: A total of 318 eyes were evaluated, 78 receiving 
beta blockers, 34 receiving brimonidine, and 206 receiving
latanoprost. The majority of patients were white males and the
mean age was 73 years. Patients receiving latanoprost had a
mean(SD) IOP reduction of 7.59(4.6)mmHg compared to
6.8(5.0)mmHg for beta-blockers (p = 0.18), and there was no
signiﬁcant difference was observed between the mean for bri-
monidine (7.1(4.7)mmHg) and beta-blockers (p = 0.76). The
mean percent change in IOP was identical for latanoprost and
brimonidine (29.6%), but only 24.8% for those receiving beta-
blockers. Average (SD) daily cost was $0.05(0.09) for beta-
blockers, $0.29(0.39) for brimonidine, and $0.30(0.42) for
latanoprost (p < 0.001). However, the most cost-effective agent
was brimonidine, with a daily cost of $7.15 for each percent
reduction in IOP. Latanoprost demonstrated a daily cost per
percent IOP reduction of US$7.58. Both brimonidine and
latanoprost were more cost-effective than the beta-blockers with
a cost-effectiveness ratio of US$8.42. The incremental cost-
effectiveness of using brimonidine or latanoprost compared to
beta-blockers was $3.23 and $5.05, respectively. CONCLU-
SIONS: The results suggest that despite a much lower cost, beta-
blockers are not more cost-effective than brimonidine or
latanoprost.
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OBJECTIVE: To determine the economic resources utilized in a
cohort of patients with age-related macular degeneration.
METHODS: An Institutional Review Board-approved, resource
utilization study determined the economic resources used by a
cohort of AMD patients over a historical 12-month period from
the societal perspective. We evaluated costs by administering an
interviewer-administered questionnaire and reviewing partici-
pants’ clinic charts. From these two data sources, we evaluated
both direct medical costs and direct non-medical costs (such as
home support and assessment and low vision rehabilitation
including CCTV magniﬁers). Indirect costs incurred by family
members related to medical visits and supportive care were eval-
uated; productivity was not evaluated due to the low employ-
ment rate in this demographic. Statistical analyses included
determining the mean and variance about the main cost drivers.
In addition, a series of multivariate models evaluated if visual
dysfunction and other clinical variables were associated with
economic resources utilized. RESULTS: The 41 subjects included
in this analysis had a mean age of 79.6 years (SD 6.1); 64% were
females. Seventy-four percent of the sample had wet AMD, and
38.4% of the sample had bilateral wet disease. The median dura-
tion of disease was 16.9 months. The mean logMAR visual
acuity of the sample was 0.51 in the better seeing eye (20/65)
and 1.17 in the worse seeing eye (20/300). The mean annual cost
per patient in this sample was $3944.62 (CND). Direct medical
costs were the main cost driver, accounting for 91% ($3605) of
total costs. Multivariate linear regression using stepwise variable
selection demonstrated that both duration (p = 0.02) and visual
acuity in the better-seeing eye (p = 0.05) were signiﬁcantly asso-
ciated with increasing consumption of direct non-medical
resources. CONCLUSIONS: The economic resources utilized by
AMD patients are high, and visual acuity in the better-seeing eye
is inversely related to direct non-medical costs.
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OBJECTIVES: To investigate whether ethnicity was associated
with differences in Medicaid eligibility, health care utilization,
and direct medical costs over time in a systemic lupus erythe-
matosus (SLE) population. METHODS: A retrospective analysis
of California Medicaid claims data was conducted on patients
with a diagnosis of SLE. The patient monitoring period spans a
7-year (84 month) timeframe. Patient eligibility and month-by-
month utilization and costs were computed and compared across
ethnic groups. Descriptive statistics are presented with ﬁgures or
tables detailing activity during the monitoring period. A mixed
regression model on patient-level data was used to verify the
trends of the aggregate data, controlling for covariates.
RESULTS: Hispanic patients have shorter eligibility compared to
other cohorts (about 50% vs. 70% remain eligible at Month 36,
respectively). Over time, Hispanics generated lower total costs
than other cohorts. Results for inpatient frequency, prescription
costs and outpatient/physician/supply costs followed similar pat-
terns. Mixed regression model ﬁndings revealed that when
adjusted for age, gender and aid program, total costs for His-
panic patients decreased as the length of care increased, in con-
trast to the experience of other ethnic groups. The interaction
between ethnicity and treatment progression measured by
quarter was signiﬁcant (p < 0.0001), but ethnicity as a main
effect was not (p = 0.091). Differences in total costs appear small
initially, but as the follow-up period gets longer, Hispanic
patients experience lower total costs. CONCLUSIONS: These
preliminary longitudinal data in a single state Medicaid program
may imply that Hispanics with lupus either have slower disease
progression than other ethnic groups, are able to return to work
faster, or have difﬁculties with access to care.
PES10
THE COST-EFFECTIVENESS OF METHYL AMINOLEVULINATE
PHOTODYNAMIC THERAPY (MAL-PDT) FOR DIFFICULT TO
TREAT ACTINIC KERATOSES
Orme ME, Howard P
Heron Evidence Development, Letchworth, Herts, United Kingdom
OBJECTIVES: Methyl aminolevulinate cream is the ﬁrst licensed
topical PDT product in the UK to treat actinic keratoses (AK).
It is activated when the cream is illuminated with a red light
source (MAL-PDT). In the UK, the incidence rate of AK is 5%.
The aim of this study was to assess the cost-effectiveness of
MAL-PDT versus the most commonly used intervention,
cryotherapy. METHODS: Clinical outcomes were obtained from
a multicentre comparative trial of difﬁcult to treat AK (Foley et
al. Journal of Dermatol Treat (2003)), deﬁned as thin or non-
hyperkeratotic AK on the face or scalp. Resource use was from
a Delphi panel of dermatologists and costs from standard UK
